Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Trinity Biotech ( (TRIB) ).
On September 30, 2025, Trinity Biotech plc held its annual general meeting where shareholders approved all proposed resolutions with at least 93% of votes. Key resolutions included the re-appointment of Grant Thornton as statutory auditor, authorization for the board to fix auditors’ remuneration, reduction of nominal value of A Ordinary Shares, increase in authorized share capital, and refreshing the board’s authority to issue new shares. Jim Walsh retired from the board but will continue as a Scientific Advisor, highlighting his long-term commitment to the company.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. While technical analysis shows some positive momentum, the poor valuation metrics further weigh down the score.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc operates in the biotechnology industry, focusing on the development, manufacture, and marketing of diagnostic products for the point-of-care and clinical laboratory markets.
Average Trading Volume: 4,433,014
Technical Sentiment Signal: Sell
Current Market Cap: $18.96M
For a thorough assessment of TRIB stock, go to TipRanks’ Stock Analysis page.